Abstract
hPYY(3-36) injections have shown positive effects on appetite regulations, sparking increased interest in hPYY(3-36) research. Of great interest is oral delivery of hPYY(3-36) that can achieve clinically relevant weight-loss outcomes in what would be a highly patient compliant route. Successful oral delivery of other peptides utilizing the vitamin B12 pathway has been shown but below clinically relevant levels. Herein, we present clinically relevant in vivo oral delivery of B12-hPYY(3-36) conjugates.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Administration, Oral
-
Animals
-
Appetite Depressants / administration & dosage*
-
Appetite Depressants / chemistry
-
Appetite Depressants / pharmacokinetics
-
Humans
-
Peptide Fragments
-
Peptide YY / administration & dosage*
-
Peptide YY / blood
-
Peptide YY / chemistry
-
Rats
-
Rats, Sprague-Dawley
-
Signal Transduction
-
Vitamin B 12 / administration & dosage*
-
Vitamin B 12 / blood
-
Vitamin B 12 / chemistry
Substances
-
Appetite Depressants
-
Peptide Fragments
-
Peptide YY
-
peptide YY (3-36)
-
Vitamin B 12